Sirion, Acucela sign deal for gene therapy development

Sirion Biotech and Acucela have signed a 2-year development agreement to establish optimized adeno-associated virus vectors for clinical applications in ocular gene therapy, according to a Sirion press release.

Through the agreement, which Acucela is using to bolster its entrance into the gene therapy market to find a genetic treatment for retinitis pigmentosa, milestone payments will be made to Sirion and additional royalties will be paid on sales from resulting products, the release said.

Sirion, which has been working with viral vector engineering for 10 years, will work with Acucela and an academic partner consortium to develop the next generation of recombinant adeno-associated virus vectors, which are considered the most promising gene delivery system for therapeutic applications, according to the release.

“The academic acumen of our partners, together with our strong viral vector specialization and experience, will empower our client to enter clinical trials with an efficient, safe and scalable product,” Christian Thirion, PhD, founder and CEO of Sirion, said in the release.

Sirion Biotech and Acucela have signed a 2-year development agreement to establish optimized adeno-associated virus vectors for clinical applications in ocular gene therapy, according to a Sirion press release.

Through the agreement, which Acucela is using to bolster its entrance into the gene therapy market to find a genetic treatment for retinitis pigmentosa, milestone payments will be made to Sirion and additional royalties will be paid on sales from resulting products, the release said.

Sirion, which has been working with viral vector engineering for 10 years, will work with Acucela and an academic partner consortium to develop the next generation of recombinant adeno-associated virus vectors, which are considered the most promising gene delivery system for therapeutic applications, according to the release.

“The academic acumen of our partners, together with our strong viral vector specialization and experience, will empower our client to enter clinical trials with an efficient, safe and scalable product,” Christian Thirion, PhD, founder and CEO of Sirion, said in the release.